Rejecting the urging of the Solicitor General, the US Supreme Court denied Teva Pharmaceuticals USA Inc.’s petition for certiorari in the contentious case involving generic label carve outs of patented indications. That leaves the US Federal Circuit Court of Appeals’ finding that Teva’s generic version of GlaxoSmithKline Pharmaceuticals Ltd.’s Coreg (carvedilol) induced infringement intact though Teva said it will continue its battle in district court.
Teva said in a statement that it is disappointed the Supreme Court denied its petition to review the case